STOCK TITAN
  1. Home
  2. News
  3. EXEL

Exelixis Inc - EXEL STOCK NEWS

Welcome to our dedicated page for Exelixis news (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis stock.

Exelixis Inc. (symbol: EXEL) is a leading biopharmaceutical company that specializes in the discovery, development, and commercialization of small molecule therapies aimed at improving cancer treatment. Founded in the early 1990s, Exelixis has dedicated the past decade to establishing a robust development platform to bring new, effective cancer therapies to patients in need.

Exelixis’s flagship product, Cometriq® (cabozantinib), received its initial regulatory approval in late 2012 and has since been a cornerstone in the company’s portfolio. Cometriq is prescribed for the treatment of metastatic medullary thyroid cancer, while its variant Cabometyx is used for treating kidney and liver cancers.

Another significant achievement is the development and commercialization of Cotellic in partnership with Roche, targeted at melanoma treatment. These therapies have not only enhanced Exelixis’s market presence but also brought substantial improvements in patient outcomes.

Exelixis remains steadfast in its commitment to clinical excellence and patient care, consistently exploring new avenues for innovative cancer treatments. The company continues to engage in rigorous research and development activities, underpinned by strategic partnerships and collaborations.

Financially, Exelixis has shown solid performance with steady revenue growth driven by its commercial products and a promising pipeline of new therapies under development. The company’s dedication to research, patient care, and financial prudence makes it a notable entity in the biopharmaceutical landscape.

For more information about Exelixis and potential job opportunities, please visit their official website at www.exelixis.com.

News

Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

Rhea-AI Summary
Exelixis, Inc. announced promising results from the phase 3 pivotal study CONTACT-02, showing a 35% reduction in the risk of disease progression or death in patients with metastatic castration-resistant prostate cancer when treated with cabozantinib in combination with atezolizumab. The study also demonstrated a statistically significant improvement in progression-free survival and a trend for overall survival. Treatment-emergent adverse events occurred in 97% of patients treated with the combination regimen compared with 87% of patients treated with a second novel hormonal therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
clinical trial
-
News

Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024

Rhea-AI Summary
Exelixis, Inc. (EXEL) will release its fourth quarter and fiscal year 2023 financial results on February 6, 2024, after the markets close. A conference call and webcast will follow to discuss the results and provide a general business update. Access to the event is available via the company’s website. The webcast replay will be archived on the website for one year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
earnings
-
News

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

Rhea-AI Summary
Bristol Myers Squibb and Exelixis, Inc. announced positive results from the CheckMate -9ER trial, showing that Opdivo in combination with CABOMETYX reduced the risk of death by 23% in the first-line treatment of advanced renal cell carcinoma vs. sunitinib. The combination also demonstrated superior progression-free survival (PFS) and objective response rates (ORR) in patients treated with Opdivo plus CABOMETYX over sunitinib, regardless of risk classification. The four-year follow-up results showed durable and clinically meaningful efficacy, with significant improvements in PFS, OS, ORR, and complete response (CR). No new safety concerns were identified in this follow-up analysis, and the combination regimen also showed benefits in patient subgroups across risk groups. The data will be presented at the ASCO GU 2024 Genitourinary Cancers Symposium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
none
News

European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets

Rhea-AI Summary
Exelixis, Inc. successfully defended its European Patent number EP2593090 against three opponents, upholding the patent as granted. The patent covers tablet formulations of cabozantinib, including the tablet formulation approved as CABOMETYX® (cabozantinib) tablets by the European Medicines Agency. The decision is specific to the European patent at issue and is subject to appeal to the EPO Technical Boards of Appeal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
none
-
News

Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

Rhea-AI Summary
Exelixis, Inc. (Nasdaq: EXEL) reported preliminary unaudited financial results for fiscal year 2023, with approximately $1.630 billion in net product revenues. The company also provided guidance for fiscal year 2024, expecting net product revenues of $1,650 million - $1,750 million and R&D expenses of $925 million - $975 million. The appointment of two new board members, corporate restructuring, and a $450 million share repurchase program were also announced.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
earnings
-
News

Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024

Rhea-AI Summary
Exelixis, Inc. (Nasdaq: EXEL) will have its President and CEO, Michael M. Morrissey, Ph.D., present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. The presentation will be webcast on www.exelixis.com, with a replay available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
conferences
News

Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023

Rhea-AI Summary
Exelixis, Inc. (Nasdaq: EXEL) will webcast the Exelixis 2023 R&D Day: Science & Strategy event on December 12, 2023, featuring speakers reviewing the company’s research and development pipeline, clinical updates, and efforts to serve more cancer patients and generate sustainable value for shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
none
-
News

Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer

Rhea-AI Summary
Exelixis, Inc. (Nasdaq: EXEL) has initiated the STELLAR-305 phase 2/3 pivotal trial to evaluate zanzalintinib in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). The trial will assess the potential of inhibition of VEGF, MET, and AXL, which are elevated in these tumors. This global, multicenter, randomized, double-blind study aims to provide a chemo-free treatment option for patients with incurable SCCHN. The primary endpoints are progression-free survival (PFS) and overall survival, with secondary endpoints including objective response rate and duration of response.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
clinical trial
-
News

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

Rhea-AI Summary
Exelixis, Inc. (EXEL) and Arcus Biosciences (RCUS) have announced a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis’ next-generation TKI, in combination with AB521, an inhibitor of the transcription factor HIF-2⍺, in patients with advanced solid tumors. Patient enrollment for STELLAR-009 is expected to begin before the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
clinical trial
News

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

Rhea-AI Summary
Exelixis, Inc. (EXEL) and Arcus Biosciences (RCUS) have announced a clinical trial collaboration for STELLAR-009, a phase 1b/2 trial evaluating zanzalintinib, Exelixis' next-generation tyrosine kinase inhibitor (TKI), in combination with AB521, an inhibitor of the transcription factor HIF-2⍺, in patients with advanced solid tumors, including clear cell renal cell carcinoma (ccRCC). The trial is expected to begin enrolling patients before the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
clinical trial

FAQ

What is the current stock price of Exelixis (EXEL)?

The current stock price of Exelixis (EXEL) is $34.83 as of November 21, 2024.

What is the market cap of Exelixis (EXEL)?

The market cap of Exelixis (EXEL) is approximately 9.9B.

What is Exelixis Inc. known for?

Exelixis Inc. is known for developing and commercializing small molecule therapies aimed at improving cancer treatment.

What are the main products of Exelixis?

The main products of Exelixis are Cometriq® (cabozantinib) for thyroid cancer, Cabometyx for kidney and liver cancer, and Cotellic for melanoma.

When was Cometriq first approved?

Cometriq received its initial regulatory approval in late 2012.

Who are the key partners of Exelixis?

Exelixis has partnered with Roche to bring Cotellic to market.

What type of cancer is Cometriq used to treat?

Cometriq is used to treat metastatic medullary thyroid cancer.

What is Cabometyx used for?

Cabometyx is used for the treatment of kidney and liver cancers.

Where can I find job opportunities at Exelixis?

Job opportunities at Exelixis can be found on their official website at www.exelixis.com.

How has the financial performance of Exelixis been?

Exelixis has shown solid financial performance with steady revenue growth driven by its commercial products and pipeline.

What kind of research does Exelixis focus on?

Exelixis focuses on the research and development of innovative therapies for cancer treatment.

What is the ticker symbol for Exelixis Inc.?

The ticker symbol for Exelixis Inc. is EXEL.

Stock EXEL logo
Exelixis Inc

Nasdaq:EXEL

EXEL Rankings

#875 Ranked by Market Cap
N/A Ranked by Dividends

EXEL Stock Data

9.94B
280.99M
1.67%
89.22%
3.19%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
ALAMEDA